360 related articles for article (PubMed ID: 29800048)
21. Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex-An update.
Balestri R; Rizzoli L; Pedrolli A; Urru SAM; Rech G; Neri I; Girardelli CR; Magnano M
J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):474-487. PubMed ID: 36300771
[TBL] [Abstract][Full Text] [Related]
22. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
Hofbauer GF; Marcollo-Pini A; Corsenca A; Kistler AD; French LE; Wüthrich RP; Serra AL
Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304
[TBL] [Abstract][Full Text] [Related]
23. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
Wataya-Kaneda M; Tanaka M; Yang L; Yang F; Tsuruta D; Nakamura A; Matsumoto S; Hamasaki T; Tanemura A; Katayama I
JAMA Dermatol; 2015 Jul; 151(7):722-30. PubMed ID: 25692384
[TBL] [Abstract][Full Text] [Related]
24. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.
Foster RS; Bint LJ; Halbert AR
Australas J Dermatol; 2012 Feb; 53(1):52-6. PubMed ID: 22309333
[TBL] [Abstract][Full Text] [Related]
25. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.
Haemel AK; O'Brian AL; Teng JM
Arch Dermatol; 2010 Jul; 146(7):715-8. PubMed ID: 20644030
[No Abstract] [Full Text] [Related]
26. Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient.
Micozkadioglu H; Koc Z; Ozelsancak R; Yildiz I
Ren Fail; 2010; 32(10):1233-6. PubMed ID: 20954988
[TBL] [Abstract][Full Text] [Related]
27. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response.
Truchuelo T; Díaz-Ley B; Ríos L; Alcántara J; Jaén P
Dermatol Online J; 2012 Jan; 18(1):15. PubMed ID: 22301052
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin.
Kaufman McNamara E; Curtis AR; Fleischer AB
J Dermatolog Treat; 2012 Feb; 23(1):46-8. PubMed ID: 20673154
[TBL] [Abstract][Full Text] [Related]
29. Targeted topical and combination laser surgery for the treatment of angiofibromas.
Bae-Harboe YS; Geronemus RG
Lasers Surg Med; 2013 Nov; 45(9):555-7. PubMed ID: 24136238
[TBL] [Abstract][Full Text] [Related]
30. [Topical sirolimus 0.4% formulation for treatment of facial angiofibromas].
Cuevas Asencio I; Albornoz López R; Salido Vallejo R; Reyes Malia M
Farm Hosp; 2012; 36(5):433-4. PubMed ID: 22858090
[No Abstract] [Full Text] [Related]
31. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions.
Tu J; Foster RS; Bint LJ; Halbert AR
Australas J Dermatol; 2014 Feb; 55(1):63-9. PubMed ID: 24359523
[TBL] [Abstract][Full Text] [Related]
32. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
Boggarapu S; Roberds SL; Nakagawa J; Beresford E
Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799
[TBL] [Abstract][Full Text] [Related]
33. Rapamycin and rapalogs for tuberous sclerosis complex.
Sasongko TH; Ismail NF; Zabidi-Hussin Z
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011272. PubMed ID: 27409709
[TBL] [Abstract][Full Text] [Related]
34. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol.
DeKlotz CM; Ogram AE; Singh S; Dronavalli S; MacGregor JL
Arch Dermatol; 2011 Sep; 147(9):1116-7. PubMed ID: 21931059
[No Abstract] [Full Text] [Related]
35. Inhibition of Angiofibromas in a Tuberous Sclerosis Patient Using Topical Timolol 0.5% Gel.
Krakowski AC; Nguyen TA
Pediatrics; 2015 Sep; 136(3):e709-13. PubMed ID: 26304829
[TBL] [Abstract][Full Text] [Related]
36. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis.
Mutizwa MM; Berk DR; Anadkat MJ
Br J Dermatol; 2011 Oct; 165(4):922-3. PubMed ID: 21692776
[No Abstract] [Full Text] [Related]
37. [Topical rapamycin solution to treat multiple facial angiofibromas in a patient with tuberous sclerosis].
Valerón-Almazán P; Vitiello M; Abuchar A; Kerdel FA
Actas Dermosifiliogr; 2012 Mar; 103(2):165-6. PubMed ID: 21861956
[No Abstract] [Full Text] [Related]
38. Facial Angiofibroma Severity Index (FASI): reliability assessment of a new tool developed to measure severity and responsiveness to therapy in tuberous sclerosis-associated facial angiofibroma.
Salido-Vallejo R; Ruano J; Garnacho-Saucedo G; Godoy-Gijón E; Llorca D; Gómez-Fernández C; Moreno-Giménez JC
Clin Exp Dermatol; 2014 Dec; 39(8):888-93. PubMed ID: 25142297
[TBL] [Abstract][Full Text] [Related]
39. Topical use of mammalian target of rapamycin inhibitors in dermatology: A systematic review with meta-analysis.
Leducq S; Giraudeau B; Tavernier E; Maruani A
J Am Acad Dermatol; 2019 Mar; 80(3):735-742. PubMed ID: 30744877
[TBL] [Abstract][Full Text] [Related]
40. Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex.
Hatano T; Ohno Y; Imai Y; Moritake J; Endo K; Tamari M; Egawa S
Orphanet J Rare Dis; 2020 Jun; 15(1):133. PubMed ID: 32487130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]